The global Human Vaccines Market valued at USD 44.26 billion in 2025 and is expected to reach USD 68.28 billion by 2035, growing at a CAGR of 4.43% during 2026–2035. This growth in the market is mainly due to widespread immunization coverage, increased infectious disease prevalence, and advancements in vaccine development techniques. Research done by agencies such as WHO and CDC suggests that the lives saved because of the vaccination programs range between 3.5 and 5 million annually.

The Human Vaccines Market remains on track to grow steadily in future years, with innovations in vaccine technology platforms such as mRNA, recombinant, and viral vectors, coupled with government backing towards their efforts towards immunization. It is proven through the recent example of the swift development and administration of over 13 billion COVID-19 vaccines globally.

The increasing number of diseases, advancements in vaccine technologies, and the rising number of immunization campaigns are boosting the market growth

Rising cases of infectious diseases including influenza, human papillomavirus (HPV), hepatitis, and novel viruses like COVID-19 & other strains are driving the usage of vaccines. The induction of mRNA vaccines with >90% efficacy seen in clinical trials has elevated vaccine development and research.

Global campaigns for vaccinations led by organizations like Gavi, the Vaccine Alliance, India and the United States are improving access to vaccines. An aging population and increased awareness have driven interest in vaccines beyond pediatric applications.

However, several obstacles persist. Some of the barriers include high R&D expenses, strict regulations and the requirement of advanced cold chains. mRNA vaccines, for example, require ultra-cold storage at -70 hide the secret codec offices, obviously with the first formulations of Pfizer.

Key Report Highlights

  • By Type: Inactivated vaccines led with a 28.74% share in 2025. mRNA vaccines are expected to grow the fastest at a 7.12% CAGR, reflecting strong adoption of newer platforms.
  • By Administration Route: Intramuscular vaccines held a 46.32% share, while intradermal delivery is set to grow at a 6.45% CAGR due to dose-sparing benefits.
  • By Disease Target: COVID-19 vaccines accounted for a 31.25% share in 2025. HPV vaccines are projected to grow the fastest at 7.34% CAGR, supported by cancer prevention efforts.
  • By Age Group: Adult vaccines captured a 39.61% share. Geriatric vaccines are expanding at a 6.98% CAGR, in line with aging population trends.
  • By End User: Hospitals dominated with a 53.12% share. Research and academic institutes are growing at a 7.21% CAGR, driven by clinical trials and innovation.
  • By Distribution Channel: Hospital pharmacies led with a 45.87% share, while online pharmacies are expected to grow at a 6.78% CAGR as digital healthcare expands.
  • By Region: North America held a 34.56% share in 2025. Asia-Pacific is the fastest-growing region with a CAGR of 5.89%.

Regional Outlook

North America held a market share of 34.56% in the Human Vaccines Market in 2025. Well-developed healthcare infrastructure, high immunization rate, and substantial research and development expenditure contribute to this trend. The childhood immunization rate in the U.S. is above 95% according to CDC statistics. This region is characterized by the presence of leading pharmaceutical companies and has a pivotal role in vaccine development, including the speedy production of mRNA vaccines against COVID-19. The U.S. continues its active participation in clinical trials and approval process.

The fastest-growing region is Asia-Pacific, which will experience an annual growth rate of 5.89% between 2026 and 2035. Population size, increased immunization initiatives, and growing manufacturing facilities are some of the factors contributing to the development of the region. Countries like India and China combined represent more than 40% of the world’s total vaccine production. The Serum Institute of India alone manufactures more than 1.5 billion doses each year. Increased awareness and healthcare availability contribute to the development of this region.

Recent Industry Developments

  • 2024: Moderna and Pfizer advanced mRNA technology from its current use in COVID-19 vaccinations to include flu, RSV, and cancer immunizations, with multiple vaccines entering Phase III clinical trials.
  • 2025: The Serum Institute of India boosted production of HPV vaccines to mitigate shortages, emphasizing cost-effective manufacturing for developing nations.
  • 2024: GSK received regulatory clearance for novel adjuvanted vaccines that enhance immunity in elderly individuals.
  • 2025: WHO-sponsored initiatives allocated additional financial resources for ensuring equal access to vaccines, especially in Africa and Southeast Asia.

Leading Companies in the Human Vaccines Market

  • Pfizer Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Sanofi (Sanofi Pasteur)
  • Moderna, Inc.
  • AstraZeneca
  • Johnson & Johnson
  • Serum Institute of India Pvt. Ltd. (SII)
  • Bharat Biotech
  • CSL Limited (including Seqirus)
  • Novavax, Inc.
  • Sinovac Biotech Ltd.
  • CanSino Biologics
  • BioNTech SE
  • CSL Behring
  • Bavarian Nordic
  • Inovio Pharmaceuticals, Inc.
  • CureVac N.V.
  • Vaxart, Inc.
  • Walvax Biotechnology Co., Ltd.